 |
 |
PRODUCT PROFILE
Latest Dublin Prices
NAME |
LATEST |
CHANGE |
|
|---|---|---|---|
| Aer Lingus | 0.67 | 0.00 | more |
| AIB | 1.11 | -0.01 | more |
| BoI | 1.25 | 0.03 | more |
| CRH | 16.83 | -0.14 | more |
| DCC | 19.61 | -0.29 | more |
| Elan | 5.22 | -0.03 | more |
| Glanbia | 2.47 | -0.05 | more |
| Grafton | 2.64 | -0.02 | more |
| Greencore | 1.33 | 0.02 | more |
| Ind. News | 0.10 | 0.00 | more |
| ILP | 3.00 | -0.03 | more |
| Ryanair | 3.40 | -0.01 | more |
| U. Drug | 2.22 | 0.00 | more |
Elan Alzheimer drug passes human trial
Tuesday, July 14 08:20:19
An Alzheimer's therapy, being developed in part by Irish biotech group Elan and fast-tracked by the US regulator, has passed its first human trials.
ELND005, which is being developed with American firm Transition Therapeutics, is designed to treat people with mild to moderate Alzheimer's disease.
Presenting phase one trial data for the annual Alzheimer's Association International Conference on Alzheimer's disease, researchers said the drug achieved "desired concentrations in human brain tissue and cerebro-spinal fluid".
This has proved an insurmountable hurdle for a number of other drugs looking to address Alzheimer's.
No significant adverse side- effects emerged during the trial.
Business World is a service of Media World Ltd. All rights reserved. While every effort has been made to ensure the accuracy of the data provided, neither Media World Ltd nor its agents or representatives will be responsible for any loss or damage on the part of users however caused. The service is for entertainment only, and no decisions, particularly investment decisions, should be taken on the basis of information supplied in the service.